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Tuberculosis is a leading infectious disease causing millions of deaths each year. How to eradicate mycobacterial persistence has
become a central research focus for developing next-generation TB drugs. Yet, the knowledge in this area is fundamentally limited
and only a few drugs, notably capreomycin and PA-824, have been shown to be active against non-replicating persistent TB bacilli.
In this study, we performed a new bioinformatics analysis on microarray-based gene expression data obtained from the public
domain to explore genes that were diﬀerentially induced by drugs between the group of capreomycin and PA-824 and the group of
mainly the ﬁrst-line TB drugs. Our study has identiﬁed 42 genes speciﬁcally induced by capreomycin and PA-824. Many of these
genes are related to stress responses. In terms of the distribution of identiﬁed genes in a speciﬁc category relative to the whole
genome, only the categories of PE/PPE and conserved hypotheticals have statistical signiﬁcance. Six among the 42 genes identiﬁed
inthisstudyareonthelistofthetop100persistencetargetsselectedbytheTBStructuralGenomicsConsortium.Furtherbiological
elucidation of their roles in mycobacterial persistence is warranted.
Copyright © 2009 L. M. Fu and S. C. Tai. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Tuberculosis (TB) is a deadly infectious disease caused by
Mycobacterium tuberculosis that typically aﬀects the lungs
(pulmonary TB) but may also occur in other organs
(extrapulmonary TB), such as the central nervous system,
lymphatic system, circulatory system, genitourinary system,
bones, joints, and the skin. M. tuberculosis infection is
extremely diﬃcult to treat mainly because of its adap-
tive ability to turn a hostile environment within human
macrophages (phagocytes) into a friendly niche for its
replication. The bacilli can persist in human tissues, at the
primary or secondary infection sites, for a long period of
time without multiplication and later be reactivated when
the host immune system is compromised. Persistent bacilli
refer to those nongrowing bacilli that, often derived from in
vivo, can grow immediately in a fresh medium [1]. Bacterial
persistence in vivo is analogous to the stationary phase
culture in vitro [2]. Nonreplicating persistence of tubercle
bacilli can be induced under hypoxia [3]. Dormant bacilli
refer to nongrowing bacilli that do not grow immediately
in a fresh medium but can be resuscitated [1]. Latent TB
infection (LTBI) is a clinical condition associated with only
a positive tuberculin skin test (i.e., evidence of infection with
M. tuberculosis) but without clinical or radiographic signs
of active disease. Persons with LTBI are at increased risk
for development of active disease, which may occur after
decades of latent infection [4]. From the above deﬁnitions,
the distinction between persistent and dormant bacilli seems
to be their rates of recovery from the nongrowing state. A
recent study shows that M. tuberculosis replicates throughout
the course of chronic TB and is restrained by the host
immune system [5], which ﬁnding suggests that the switch
between the nonreplicating and slow replicating states is a
dynamic process subject to host immunity. In the text, we do
not make distinction between “nonreplicating persistence”2 International Journal of Microbiology
and “dormancy”. The presence of dormant tubercle bacilli
in animal tissues is best demonstrated in a well-known
Cornell model [6]. In this model, some mice infected
with M. tuberculosis and then treated with a short-term
chemotherapy (INH plus PZA) for 3 months developed
a relapse after discontinuation of the therapy. Dormancy
can cause phenotypic drug resistance. In the Cornell model
[6], the bacilli recovered from the relapsed mice were fully
susceptible to INH and PZA, indicating phenotypic rather
than genetic drug resistance associated with dormant bacilli.
Eradicating mycobacterial persistence would be an indis-
pensable element for development of next-generation TB
drugs. Recently, much research eﬀort has been focused on
testing capreomycin and PA-824 for TB treatment with
emphasis on their unique bactericidal eﬀect on persistent
tubercle bacilli. Capreomycin is an old antibiotic for treat-
ment of pulmonary tuberculosis [7] with recently increas-
ing interest. Capreomycin is eﬀective against (Multi-Drug
resistant) MDR and intracellular TB bacilli [8]. A recent
study demonstrates that among known anti-TB drugs, only
capreomycin is active against nonreplicating M. tuberculosis
bacilli in an in vitro model of persistence [9]. Capreomycin
is thus important because it can deal with both MDR and
latent TB. PA-824 exhibits bactericidal activity against both
replicating and static (persistent) tuberculosis and it also
has potent bactericidal activity against MDR M. tuberculosis
in animal infection models [10]. PA-824 shows a better
sterilizing activity than moxiﬂoxacin [11] and could enhance
bactericidal activity of rifampin and/or pyrazinamide [12].
Both capreomycin and PA-824 inhibit protein synthesis [10,
13]; PA-824 also inhibits the synthesis of cell wall lipid
[10]. Yet, how these two drugs eradicate persistent bacilli is
unclear.
In this work, we conducted an exploratory analysis of
diﬀerential gene expression in response to capreomycin and
PA-824 versus the current ﬁrst-line TB drugs in an attempt
to identify drug targets potentially linked to the unique
drug action against nonreplicating TB bacilli. Our study
found that the genes signiﬁcantly diﬀerentially expressed
in response to capreomycin and PA-824 were dominated
by PE/PPE or conserved hypotheticals, and many of these
genes were related to stress responses. These genes and
their products may serve as new drug targets for TB drug
development.
2.MaterialsandMethods
We performed diﬀerential gene expression analysis between
two sets of data samples such that one set of samples was
derived from drugs that were bactericidal to nonreplicating
persistent TB bacilli (deﬁned as the goal property) and the
other set of samples from drugs that lacked this property.
The ﬁrst set of samples served as the experimental group
whereasthesecondsetasthecontrolgroup.Onlyafewdrugs
have experimentally demonstrated the bactericidal eﬀect on
persistent M. tuberculosis g r o w ni na na n a e r o b i co rh y p o x i c
condition. In the present study, the experimental group con-
sistedoftwobest-knowndrugsinthiscategory:capreomycin
and PA-824. All ﬁrst-line TB drugs were selected to be
includedinthecontrolgroupexcept(pyrazinamide)PZAfor
the reason stated later. A second-line TB drug, ethionamide,
and a non-TB drug, ampicillin, were also added to the
control group. Fluoroquinolones were not included in this
study because current evidence is inconsistent about their
activity against persistent TB bacilli.
3. Data Collection
The microarray-based gene expression data were collected
from the GEO (Gene Expression Omnibus) database at
NCBI (National Center for Biotechnology Information)
of NIH (National Institutes of Health) at http://www
.ncbi.nlm.nih.gov/geo/. In GEO, the data are stored in
a relational database with three top-level entity types:
platforms, samples, and series. A platform describes the
format or model of the microarray (e.g., oligonucleotides,
cDNAs, etc.). A sample describes the gene expression data of
a single hybridization under a given experimental condition.
A series consists of the related samples in an experiment.
The original data were generated by treating M. tuberculosis
H37Rv with a wide variety of metabolic inhibitors, including
TB drugs, using a cDNA platform in a study conducted
by Boshoﬀ et al. [14], where the details of original data
collection can be found. The gene expression data of the
present study comprised samples of the following accession
numbers: GSM28106, GSM28096, GSM28246, GSM28245,
GSM28062, GSM28055, GSM28037, GSM28060,GSM28065
and GSM28063, which were collected under the series
GSE1642.
4.SigniﬁcanceAnalysisof Microarrays
The (Signiﬁcance Analysis of Microarrays) SAM program
can eﬀectively recognize diﬀerentially expressed genes with
high statistical signiﬁcance from multiple data sets of two
or more classes by using balanced perturbation of repeated
measurements and minimization of the false discovery rate
(FDR) [15]. FDR, as an alternative to the traditional P-
value, has been widely accepted for gene selection from
microarray data. Through balanced perturbation of repeated
m e a s u r e m e n t s ,S A Mp r o v e st ob em o r er o b u s tt h a nt r a d i -
tional statistical tests such as the t-test. In the present study,
we applied SAM version 3.0 to determine signiﬁcant genes
that were diﬀerentially expressed in gene expression proﬁling
between the experimental and control groups. The data used
in the present study, organized in the excel format ready to
be processed by SAM, can be downloaded from our web
site (http://www.patcar.org/Research/IJMB-2009.html). The
data were processed by SAM with the following parameter




The chance probability of identifying n genes among which
i genes belong to a functional category of size f is computedInternational Journal of Microbiology 3






















Figure 1: The SAM plot where the signiﬁcant genes are distributed
at the two ends. Signiﬁcant: 242, Median number of false positives:
11.31, False Discovery Rate (%): 4.67, Tail strength (%): 36.2, and
se (%): 25.1
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where g is the total number of genes in the genome.
6. Results
6.1. Genes Diﬀerentially Expressed in Capreomycin and PA-
824. SAM analysis on two classes of gene expression samples
yielded positive and negative signiﬁcant genes. Positive
signiﬁcant genes refer to genes more strongly induced in
the experimental group than in the control group, whereas
negative signiﬁcant genes are genes less strongly induced in
the experimental group compared with the control group. In
this study, the four gene-expression data samples concerning
the responses of M. tuberculosis to capreomycin and PA-824
at a low and high doses constituted the experimental group,
and the rest of data samples representing the responses of M.
tuberculosis to other selected drugs is assigned to the control
group.Consequently,positivesigniﬁcantgenesaregenesthat
are diﬀerentially expressed in response to capreomycin and
PA-824. Since capreomycin and PA-824 are bactericidal to
nonreplicating TB bacilli, genes induced by these two drugs
but not by the other drugs in the control group would likely
be linked to bactericidal activity against nonreplicating TB
bacilli,asthisisthemainattributethatdiﬀerentiatesbetween
the two groups.
SAM analysis on the gene expression data collected
for this study generated 42 positive signiﬁcant genets
and 196 negative signiﬁcant genes (Figure 1). Genes were
removed from consideration if they were not induced by
capreomycin or PA-824. In the drug-treated gene-expression
proﬁling experiment, induced genes are more signiﬁcant
than repressed genes since the induction of certain genes
reﬂectsthefeedbackorcompensatorymechanismthatsenses
the interruption of the drug-acting metabolic pathways in
which the genes are involved [17]. Our prior data also
suggest that whereas the molecular characteristics of the
inducedgenesreﬂectthedrug’smodeofaction,therepressed
genes are often nonspeciﬁc or secondary [18]. Therefore,
we focused our attention on the positive genes. Those
genes diﬀerentially induced by capreomycin and PA-824 are
displayed in Table 1 and their gene expression values across
all the drugs are summarized in Table 2. Functional analysis
of these genes would provide further insight into the main
issue.
6.2. Functional Analysis of Identiﬁed Genes. The genes dif-
ferentially expressed in response to capreomycin and PA-824
fall in seven functional categories (Table 3). The number of
the genes identiﬁed from a functional category is considered
statistically signiﬁcant at a level of signiﬁcance of 0.05 if
the associated chance probability is less than 0.005 after the
adjustment for the multiplicity eﬀect due to 10 categories. By
this criterion, PE/PPE and conserved hypotheticals are the
only categories with statistical signiﬁcance, while identiﬁca-
tion of the genes in other categories could be explained by
chance.
Thepersistence-relatedgenesidentiﬁedinthisstudywere
interpreted in terms of their functions and roles based on
current research evidence (Table 4). These genes are involved
in stress (hypoxia, starvation, or heat-shock) responses,
fatty acid degradation/catabolism for energy utilization,
membrane function, survival (i.e., essential genes), growth,
or sulfur metabolism. Yet, many genes identiﬁed in the
present study are conserved hypotheticals with unknown
function. Further biological validation on these genes is
warranted.
7. Discussion
In the present study, we collected two sets of gene expression
data samples from the GEO database so that one set of
samples was derived from drugs that were active against
nonreplicating persistent TB bacilli and the other set of
samples from drugs that were not. We used a standard dif-
ferential gene expression analytical method [25] developed
in the ﬁeld of functional genomics [26]. The gene expression
data were generated in a study that was aimed to gain new
insightintodrugmechanismsofactionbyperformingalarge
scale of gene expression proﬁling experiments concerning
M. tuberculosis responses to a variety of metabolic inhibitors
[14]. Their study, however, did not address the mechanisms
againstnonreplicatingM.tuberculosisaswedidinthepresent
study.
PZA is used in combination with other ﬁrst-line TB
drugs in order to reduce the required treatment duration
[27]. In addition, PZA in conjunction with rifampin can be
u s e dt ot r e a tl a t e n tt u b e r c u l o s i s[ 28]. These two facts suggest
that a potential role PZA may play in killing persistent TB
bacilli, despite that PZA alone did not show this property
experimentally [9]. Because of this uncertainty, PZA was not
included in the control group.
The data were generated from gene expression experi-
ments carried out on aerobic growing bacilli rather than on
anaerobic dormant bacilli. Research based on global gene4 International Journal of Microbiology
Table 1: Genes diﬀerentially induced in response to capreomycin and PA-824 relative to other drugs.
ORF Gene Product/Function Score q-value %
Rv2657c — Probable phirv2 prophage protein 4.73 0
Rv2374c hrcA Probable heat shock protein transcriptional repressor 4.12 0
Rv0354c PPE7 PPE family protein 3.80 0
Rv1364c — Conserved hypothetical protein 3.54 0
Rv2304c — Hypothetical protein 3.52 0
Rv0367c — Hypothetical protein 3.30 0
Rv0607 — Hypothetical protein 3.26 0
Rv2466c — Conserved hypothetical protein 3.21 0
Rv0830 — Conserved hypothetical protein 3.18 0
Rv2557 — Conserved hypothetical protein 3.16 0
Rv2142c — Hypothetical protein 3.02 0
Rv0654 — Probable dioxygenase 2.99 0
Rv1977 — Conserved hypothetical protein 2.99 0
Rv2688c — Probable antibiotic-transport ATP-binding protein 2.98 0
Rv1285 cysD Probable sulfate adenylyltransferase subunit 2 2.82 1.04
Rv0047c — Conserved hypothetical protein 2.77 1.73
Rv2878c mpt53 Soluble secreted antigen mpt53 precursor 2.74 1.73
Rv2254c — Probable integral membrane protein 2.63 1.86
Rv1986 — Probable conserved integral membrane protein 2.60 1.86
Rv2777c — Conserved hypothetical protein 2.60 1.86
Rv2413c — Conserved hypothetical protein 2.59 1.86
Rv1929c — Conserved hypothetical protein 2.59 1.86
Rv3288c usfY Putative protein 2.57 1.86
Rv2535c PEPQ Probable cytoplasmic peptidase 2.54 2.27
Rv2634c PE PGRS46 PE PGRS family protein 2.54 2.27
Rv1646 PE17 PE family protein 2.49 2.72
Rv2749 — Conserved hypothetical protein 2.46 2.72
Rv3452 cut4 Probable cutinase precursor cut4 2.44 3.22
Rv0192 — Conserved hypothetical protein 2.41 3.22
Rv1687c — Probable conserved ATP-binding protein ABC transporter 2.41 3.22
Rv1087 PE PGRS21 PE PGRS family protein 2.37 4.35
Rv1566c — Possible inv protein 2.36 4.35
Rv2504c scoA Probable succinyl-coa3-ketoacid-coenzyme A transferase 2.35 4.35
Rv0834c PE PGRS14 PE PGRS family protein 2.33 4.35
Rv0274 — Conserved hypothetical protein 2.33 4.35
Rv2162c PE PGRS38 PE PGRS family protein 2.30 4.35
Rv0365c — Conserved hypothetical protein 2.30 4.35
Rv3550 echA20 Probable enoyl-CoA hydratase 2.27 4.67
Rv3367 PE PGRS51 PE PGRS family protein 2.26 4.67
Rv2802c — Hypothetical arginine and alanine rich protein 2.25 4.67
Rv2291 sseB Probable thiosulfate sulfurtransferase 2.25 4.67
Rv3189 — Conserved hypothetical protein 2.25 4.67
∗ Score: the t-statistic score. q-value: the level of signiﬁcance based on SAM.
expression proﬁling has identiﬁed genes that are diﬀeren-
tially expressed by M. tuberculosis resident in macrophages
compared with M. tuberculosis grown in standard broth
culture [29]. Despite recent progress in this area, the genetic
responses of intracellular M. tuberculosis exposed to drugs
have not yet been studied. Thus, the present study was
limited by this fact. Research shows that gene expression in
a hypoxic condition reﬂects the fact that many metabolic
pathways are repressed and speciﬁc hypoxic response path-
ways are turned on. In our prior study on capreomycin,
the upregulation of isocitrate lyase (ICL) suggests that
capreomycin can aﬀect the glyoxylate shunt, which is a
pathway alternative to the tricarboxylic acid (Krebs) cycle
and is involved in intracellular mycobacterial persistenceInternational Journal of Microbiology 5
Table 2: The expression values (log2 ratios) of genes more strongly induced by capreomycin and PA-824 than the other drugs.
ORF Gene Exp1 Exp2 Exp3 Exp4 Cont1 Cont2 Cont3 Cont4 Cont5 Cont6
Rv2657c — 1.614 1.825 2.209 1.278 −0.3 −0.81 −0.54 0.42 −0.29 −0.67
Rv2374c hrcA 1.472 1.747 1.461 0.375 −0.36 −0.58 −0.57 −0.31 −0.41 −0.56
Rv0354c PPE7 0.855 0.881 0.777 1.236 −0.51 0 −0.63 0 −0.58 −0.37
Rv1364c — 1.309 1.01 0.685 1.05 −0.03 0.081 0.069 −0.42 −0.52 −0.36
Rv2304c — 0.893 1.17 1.051 1.16 0.115 −0.29 −0.31 0.35 0.015 −0.01
Rv0367c — 1.018 1.198 1.933 1.452 0.057 −0.02 0.093 0.647 0.103 −0.29
Rv0607 — 0.978 0.362 0.828 0∗ −0.77 −0.39 −0.78 −0.69 −0.77 −1.33
Rv2466c — 2.283 3.242 0.831 1.869 −0.06 0.10 .025 0.755 −0.01 0.022
Rv0830 — 1.305 0.786 0.748 0.78 −0.13 0.137 −0.08 0.041 −0.26 0∗
Rv2557 — 0.417 1.064 1.104 1.28 −0.07 0.039 0.064 −0.34 −0.15 −0.25
Rv2142c — 2.194 2.353 0.92 1.099 −0.35 00∗ −0.18 −1.24 0.668 00∗
Rv0654 — 2.31 .345 1.277 0.908 −0.13 −0.95 −0.53 0.726 −0.04 −0.08
Rv1977 — 0.395 0.434 0.537 0.61 −0.28 −0.65 −0.23 −0.36 −0.1 −0.32
Rv2688c — 1.033 1.686 1.289 2.103 0.329 −0.15 0.063 0.73 0.093 0.547
Rv1285 cysD 2.109 1.628 2.463 0.746 −0.20 .158 −0.15 1.181 −0.13 −0.16
Rv0047c — 1.31 1.796 1.446 1.461 −0.09 −0.29 1.12 −0.52 −0.29 0.633
Rv2878c mpt53 0.639 1.564 0.473 0.733 −0.27 −0.21 −0.68 0.013 −0.4 −0.01
Rv2254c — 1.795 2.008 0.324 0.305 −0.2 −0.23 −0.76 −0.62 −0.07 −0.34
Rv1986 — 2.467 2.354 1.131 0.666 0.295 0∗ 0.096 0.814 −0.15 0∗
Rv2777c — −0.26 2.052 1.453 0.792 −0.88 −0.11 −0.74 −0.21 −1.17 −0.46
Rv2413c — 0.854 0.565 1.435 0.438 0.012 −0.06 −0.71 −0.09 −0.03 −0.4
Rv1929c — 0.71 0.581 1.359 0.721 0.004 −0.12 0.078 0.172 0.023 −0.31
Rv3288c usfY 1.688 1.397 1.253 0.31 0.153 0.325 −0.09 0.191 −0.12 −0.07
Rv2535c PEPQ 0.646 0.956 −0.07 0.451 −0.53 −0.2 −0.16 −0.61 −0.77 −0.63
Rv2634c PE PGRS46 0.673 0.494 0.473 0.765 −0.09 −0.39 −0.03 0.028 −0.03 −0.56
Rv1646 PE17 1.947 2.987 0.451 1.528 −0.24 0∗ −0.32 1.113 −0.48 0.124
Rv2749 — 0.669 0.611 0.597 1.069 0.138 0.11 0.083 0.014 0.065 0.118
Rv3452 cut40 .753 0.932 1.36 0.673 0.244 0.259 0.097 0.176 0.156 0.271
Rv0192 — 0.74 1.674 1.227 0.694 0.424 0.158 −0.04 0.044 0.365 0.077
Rv1687c — 0.894 0.446 1.547 0.726 0.19 0.177 0.051 −0.33 −0.02 −0.33
Rv1087 PE PGRS21 0.553 0.361 0.797 0.474 −0.10 .075 −0.14 −0.24 0.039 −0.28
Rv1566c — 1.732 1.274 1.451 1.097 0.513 −0.16 0.835 −0.61 0.685 0.352
Rv2504c scoA 0.675 0.915 1.978 0.376 −0.28 0.095 −0.66 0.396 −0.49 −0.38
Rv0834c PE PGRS14 0.69 1.236 0.827 1.372 0.147 0.417 0.382 0.455 0.141 0.073
Rv0274 — 0.189 0.424 1.123 1.799 −0.19 0.002 −0.49 −1.47 −0.11 −0.41
Rv2162c PE PGRS38 0.631 1.093 0.436 0.478 −0.1 −0.14 −0.34 0.191 −0.04 −0.04
Rv0365c — 0.134 0.174 0.808 0.243 −0.43 −0.15 −0.64 −0.5 −0.24 −0.57
Rv3550 ECHA20 1.082 −0.22 1.71 .633 −0.33 0.121 −0.5 −0.09 −0.35 0∗
Rv3367 PE PGRS51 0.065 0.223 0.874 0.57 −0.57 0.197 −0.49 −0.53 −0.63 −0.71
Rv2802c — −0.15 0.542 0.319 0.016 −0.31 −0.5 −0.95 −0.42 −0.66 −0.68
Rv2291 sseB 0.528 0.31 1.646 0.867 −0.18 −0.09 −0.35 −0.01 −0.04 0.071
Rv3189 — 2.111 1.681 3.122 1.608 −0.43 0.287 −0.22 1.945 1.349 0∗
Exp1-2: capreomycin. Exp3-4: PA-824. Cont1: INH. Cont2: rifampin. Cont3: ethambutol. Cont4: streptomycin. Cont5: ethionamide. Cont6: Ampicillin.
∗The default value in the case of missing values.
when fatty acids become a major source of carbon and
energy in M. tuberculosis metabolism [30]. Although that
study was conducted in an aerobic condition, the gene
expression pattern found there also revealed responses to the
nonreplicating state due to the drug’s action.
Another limiting factor in the present study is due to
the fact that the observed bactericidal eﬀect of capreomycin
and PA-824 on nonreplicating bacilli is based on the Wayne
model [3], which has been widely adopted for this purpose,
but its accuracy for simulating the in vivo nonreplicating6 International Journal of Microbiology
Table 3: Functional classes of genes strongly induced by capreomycin and PA-824 relative to other TB drugs. P = the chance probability
of the number of the genes identiﬁed from a given functional category among all genes. Functional classes are based on TubercuList
(http://genolist.pasteur.fr/TubercuList/).
Functional class Induced genes Induced gene No. (P-value) All genes in the Class
0 virulence, detoxiﬁcation, adaptation Rv2374C Rv1566C 2 (0.275) 212
1 lipid metabolism Rv2504C Rv3550 2 (0.264) 237
2 information pathways None 0 (N/A) 232
3 c e l lw a l la n dc e l lp r o c e s s e s Rv2688C Rv2878C Rv2254C 6 (0.129) 751
Rv1986 Rv3452 Rv1687C
4s t a b l e R N A s N o n e 0 ( N / A ) 5 0
5 insertion seqs and phages Rv2657C 1 (0.333) 147
6 PE/PPE
Rv0354C Rv2634C Rv1646
7 (0.001) 168 Rv1087 Rv0834C Rv2162C
Rv3367
7 intermediary metabolism & respiration Rv0654 Rv1285 Rv2535C 4 (0.018) 898
Rv2291
8 unknown None 0 (N/A) 15
9 regulatory proteins None 0 (N/A) 194









state has been questioned. Despite the above limitations, the
present ﬁndings would serve as a basis for future work.
The pathogenicity of M. tuberculosis involves a complex
set of factors. The availability of the M. tuberculosis genome
sequence coupled with advances in molecular biology has
resulted in a wide range of novel drug targets related
to transcription, cell wall synthesis, signal transduction,
information pathway, intermediate metabolism, virulence,
and persistence [31]. The need of lengthy chemotherapy
reﬂects the lack of adequate understanding in bacterial
persistence. However, a ﬁnding that the persistence of M.
tuberculosis in mice requires the glyoxylate shunt enzyme
isocitrate lyase (ICL) [32] points to a new drug target. Other
possible drug targets related to TB persistence are DosR,
RelA, and PcaA [31]. As there have been only a handful
of drug targets hypothesized as relevant to mycobacterial
persistence to date and the prospect of their serving as
a basis for developing a practically useful new TB drug
is uncertain, our study is aimed to address this issue by
taking a genomewide approach to ﬁnding new TB drug
targets.
The in vivo microenvironment of persistent TB bacilli
is often located in such lesions as granulomas, cavities, or
caseous tissue necrosis, where oxygen and nutrients are both
deprived. Stress results from hypoxia and starvation as well
as host immunity. To survive, TB bacilli must activate certain
metabolic pathways to deal with the stress. Such rescue
pathwayshavebeenstudiedforhypoxia[33],starvation[20],
and high temperature [21].
Six among the 42 genes identiﬁed in the present study are
onthelistofthetop100persistencetargetsselectedbytheTB
Structural Genomics Consortium (http://www.webtb.org/).
These genes are: Rv2557, Rv1285, Rv2878C, Rv2777C,
Rv1929C, and Rv0834C. The chance probability of identify-
ing 42 genes from all genes in the M. tuberculosis genome
such that 6 genes are in the category of the 100 persistence-
related genes is.0005, and hence it is highly statistically
signiﬁcant in this sense. It is not clear how the relevance to
persistence is assessed for those top 100 persistence targets,
but it is presumably based on evidence derived from long-
term research eﬀorts on M. tuberculosis conducted by the
Consortium members. There is no guarantee that these
top targets are the best drug targets for future TB drug
development. Nevertheless, the overlap of our ﬁndings with
the data provided by the Consortium is signiﬁcant and oﬀers
credence to the ﬁndings.
It is interesting to note that none of the identiﬁed
genes belong to information pathways or to regulatory
proteins. Some well-known TB drugs target information
pathways. For example, rifampin targets RNA polymerase,
ﬂuoroquinolones target DNA gyrase, and streptomycin
targets ribosomal protein and 16S rRNA. These drugs are
eﬀective against actively growing TB bacilli, but they cannot
eradicate persistent bacilli. In contrast, capreomycin and PA-
824 target not only information pathways but also other
metabolic pathways. Our analysis suggests that inhibition of
the information pathway alone is not suﬃcient for resolving
the issue of mycobacterial persistence.International Journal of Microbiology 7




Required for survival in primary murine
macrophage [19]
Regulation of heat-shock proteins




Rv0367c — Upregulated at high temperatures [21]
Rv0607 — Essential gene [22]
Rv2466c — Upregulated at high temperatures [21]
Rv0830 — Unknown
Rv2557 —
Upregulated after 24hours and 96hours
of starvation [20]
Expression in human lung granulomas
[23]
Rv2142c — Unknown
Rv0654 — Upregulated at high temperatures [21]
Rv1977 — Unknown
Rv2688c — Unknown
Rv1285 cysD Upregulated at high temperatures [21]






Rv2777c — Upregulated at high temperatures [21]
Rv2413c — Upregulated after 4hours of starvation
[20]
Rv1929c — Upregulated after 96hours of starvation
[20]
Rv3288c usfY Upregulated after 24hours and 96hours
of starvation [20]
Rv2535c PEPQ Impaired growth [22]






Rv1087 PE PGRS21 Unknown
Rv1566c — Unknown
Rv2504c scoA Involved in fatty acid degradation and
synthesis [24]
Rv0834c PE PGRS14 Unknown
Rv0274 — Upregulated after 4hours, 24hours and
96hours of starvation [20]
Rv2162c PE PGRS38 Unknown
Rv0365c — Involved in survival in macrophages [19]8 International Journal of Microbiology
Table 4: Continued.
ORF Gene ExistingEvidence
Rv3550 ECHA20 Fatty acid degradation [24]





The distribution of the genes identiﬁed in the categories
of virulence, lipid metabolism, cell wall and cell processes,
intermediary metabolism and respiration is not statistically
signiﬁcantly diﬀerent from their distribution in the whole
genome. Thus, the signiﬁcance of these gene categories as
relevance to mycobacterial persistence is questionable. For
example, isoniazid, the best known ﬁrst-line TB drug, works
by inhibiting mycobacterial cell wall synthesis but it is not
eﬀective against persistent TB bacilli [9].
PE/PPE and conserved hypotheticals are the only two
functional categories where the distribution of the genes
identiﬁed in this study is signiﬁcantly diﬀerent from their
distribution in the whole genome. This ﬁnding suggests
that a signiﬁcant number of genes pertinent to persistence
elimination are likely PE/PPE or conserved hypothetical
proteins. If this hypothesis turns out to be true, then it
explainswhythepersistenceproblemisdiﬃculttosolvesince
the current knowledge about genes in these two categories is
quite limited. Elucidation of the functions of these PE/PPE
and hypothetical proteins could result in information useful
for developing new TB drugs. The investigation of some of
these genes related to persistence is currently underway, for
example, Rv2557, Rv2777c, and Rv1929c in the hypothetical
category, and Rv0834c in the PE family.
About 10% of the genes in M. tuberculosis genome are
dedicated to the production of two families of glycine-
rich proteins called PE (proline-glutamine motifs) and
(proline-proline-glutamine motifs) PPE, characterized by
repetitive structure that may represent a source of antigenic
variation [24]. It is logical to assume that suppression of the
PE/PPE synthesis pathway may reduce antigenic variation
and thereby facilitate the bactericidal mechanisms due to
host immunity; however, this hypothesis remains to be
proven.
8. Conclusion
The treatment of M. tuberculosis infection is often diﬃcult
mainly because of its adaptive ability to persist in the host
tissue for a long period of time. Eradicating mycobacterial
persistence would be an indispensable element for develop-
ing next-generation TB drugs. Yet, our understanding of the
mechanisms of persistence is still far from reaching the point
where an eﬀective new drug can be developed to solve the
problem. In fact, only a handful of genes are found to be
potential drug targets pertinent to mycobacterial persistence,
and only a few drugs exhibit bactericidal activity against
nonreplicating TB bacilli, notably, capreomycin and PA-
824. In the present study, we identiﬁed genes diﬀerentially
expressed in response to capreomycin and PA-824 versus the
ﬁrst-line TB drugs. Six genes identiﬁed in our study are on
the list of the top 100 persistence targets selected by the TB
Structural Genomics Consortium. A signiﬁcant number of
genes identiﬁed are PE/PPE or conserved hypotheticals, and
many of these genes are related to stress responses. Further
biological validation on these genes is warranted.
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